What the studies show
Hexarelin binds a receptor (CD36) in the heart and has cardiovascular effects in animals and acute human physiology studies. No controlled trial has tested a clinical cardiac outcome.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Arvat E, et al. Endocrine activities of ghrelin in humans: comparison with hexarelin and GHRH.J Clin Endocrinol Metab, 2001;86:1169–1174Acute GH-releasing potency of hexarelin in people.
In context
Hexarelin is a synthetic six-amino-acid growth-hormone-releasing peptide. Single doses cause a strong, well-documented growth-hormone spike in humans, but the one study of continued use showed the response fades within weeks and that IGF-1 and body composition did not meaningfully change. It was never developed into an approved medicine, and the muscle, fat-loss and cardiac claims made for it have no controlled human evidence.
Hexarelin is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Hexarelin proven to help with cardiac effects?
What studies are behind the grade?
Is Hexarelin approved for this?
Other outcomes for Hexarelin
- CGrowth hormone releaseMultiple acute studies + 1 chronic study
- DBody composition1 chronic study (n small)
- CSafety in humansadverseEarly-phase
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →